NASDAQ:ARGX
argenx SE Stock News
$365.81
-10.79 (-2.87%)
At Close: May 17, 2024
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
04:12pm, Monday, 20'th Mar 2023 Benzinga
HC Wainwright has increased the price target on Immunovant Inc (NASDAQ: IMVT) and reiterates a Buy rating.
The analyst says it has updated the model as the company is now pursuing warm autoimmune
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
08:01pm, Friday, 17'th Mar 2023 GlobeNewswire Inc.
March 17, 2023
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
01:25pm, Wednesday, 15'th Mar 2023 GlobeNewswire Inc.
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antib
5 Analysts Have This to Say About argenx
01:01pm, Friday, 03'rd Mar 2023 Benzinga
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
0
0
0
Last 30D
1
0
argenx Announces Planned Transition of Chief Operating Officer
06:00am, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
March 2, 2023
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
06:00am, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
$173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales
argenx Appoints Steve Krognes to Board of Directors
09:01pm, Monday, 27'th Feb 2023 GlobeNewswire Inc.
February 27, 2023
argenx to Present at Upcoming Investor Conferences
06:00am, Monday, 27'th Feb 2023 GlobeNewswire Inc.
February 27, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
argenx to Present at Upcoming Investor Conferences
01:00am, Monday, 27'th Feb 2023
February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
06:00am, Thursday, 23'rd Feb 2023 GlobeNewswire Inc.
February 23, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
01:00am, Thursday, 23'rd Feb 2023
February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
03:40pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
04:54pm, Monday, 20'th Feb 2023 Zacks Investment Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Immunovant Could Potentially Be An M&A Target, Writes Analyst
06:14pm, Wednesday, 15'th Feb 2023 Benzinga
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30.
The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, f
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important
01:10pm, Monday, 06'th Feb 2023
argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher
